Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00800007 · ClinicalTrials.gov registry record · Phase 1
Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus
A Phase 1 study, sponsored by Anza Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00800007 is a Phase 1 study that was terminated before completion, run by Anza Therapeutics. The registered enrollment target is 5 participants.
The verdict
NCT00800007, a Phase 1 study, was terminated before completion, sponsored by Anza Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, immunogenicity, and antiviral effects of multiple intravenous doses of ANZ-521 in patients with chronic Hepatitis C virus.
Interventions
- DRUG Placebo
- DRUG ANZ-521
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00800007
The ClinicalTrials.gov registry entry for NCT00800007 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anza Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00800007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00800007 about?
NCT00800007 is a clinical study titled "Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus". The purpose of this study is to evaluate the safety, immunogenicity, and antiviral effects of multiple intravenous doses of ANZ-521 in patients with chronic Hepatitis C virus.
What is the current status of trial NCT00800007?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2008-11. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00800007?
The interventions under investigation include: Placebo (DRUG), ANZ-521 (DRUG).
Who is sponsoring clinical trial NCT00800007?
This trial is sponsored by Anza Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.